OPTIMAL PROPHYLACTIC PLATELET DOSE STRATEGY / THROMBOCYTOPENIC PATIENTS

最佳预防性血小板剂量策略/血小板减少症患者

• 批准号: 7607264
• 负责人: STEVEN R SLOAN
• 金额: $ 17.01万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607264
• 关键词: Blood Platelets; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Hemorrhage; Institution; Patients; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Upper arm; experience; prophylactic

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To compare the three study arms of medium, lower, and higher dose platelet therapy with respect to the percentage of patients experiencing at least one episode of Grade 2 or higher bleeding as determined by the Platelet Dose Trial Bleeding Scale.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 比较中等、较低和较高剂量血小板治疗的三个研究组，根据血小板剂量试验出血量表确定的至少经历一次 2 级或以上出血的患者百分比。